FDA reopens comment period
This article was originally published in The Tan Sheet
Executive Summary
FDA will reopen until May 18 the comment period on issues relating to its regulations for chemistry, manufacturing and controls supplements and other changes to approved marketing applications for human drugs, according to a Federal Register notice slated for publication April 16. The agency conducted a public meeting in February to consider comments on issues it should consider in revising those regulations, as required by the FDA Modernization Act of 1997 (1"The Tan Sheet" Feb. 26, 2007, p. 12)...
You may also be interested in...
FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs
Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.